Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17627531 | 0.92 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL32670136 | 0.90 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2168188 | 0.89 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5494602 | 0.88 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2635503 | 0.88 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15226208 | 0.88 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL23611360 | 0.88 | P2RY14 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4415322 | 0.87 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17745010 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL23673342 | 0.84 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234792-A1 | SYSTEMS AND METHODS FOR TRANSVENOUS LEAD IMPLANTATION | CARDIAC PACEMAKERS, INC. (US) | 2008-09-25 | — | — | US | claimed |
| CN-115969854-A | Treatment of cancer with TG02 | 科瑞华生物技术有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-109195603-B | Treatment of cancer with TG02 | 科瑞华生物技术有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-113438947-A | Combination therapy of DON prodrugs and immune checkpoint inhibitors | 羿尊生物医药股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-10184113-B2 | Ex vivo human multiple myeloma cancer niche and its use as a model for personalized treatment of multiple myeloma | HACKENSACK UNIVERSITY MEDICAL CENTER (US) | 2019-01-22 | — | — | US | disclosed |
| US-20160137986-A1 | EX VIVO HUMAN MULTIPLE MYELOMA CANCER NICHE AND ITS USE AS A MODEL FOR PERSONALIZED TREATMENT OF MULTIPLE MYELOMA | HACKENSACK UNIVERSITY MEDICAL CENTER | 2016-05-19 | — | — | US | disclosed |
| US-9267938-B2 | Ex vivo human multiple myeloma cancer niche and its use as a model for personalized treatment of multiple myeloma | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140274953-A1 | EX VIVO HUMAN MULTIPLE MYELOMA CANCER NICHE AND ITS USE AS A MODEL FOR PERSONALIZED TREATMENT OF MULTIPLE MYELOMA | HACKENSACK UNIVERSITY MEDICAL CENTER | 2014-09-18 | — | — | US | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | SLC28A1 1135/4885SLC28A2 1281/4885SLC29A1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.